SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4cak'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1CMC_A_SAMA105_0
(MET REPRESSOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 10 GLY A 282
GLU B 500
LEU B 502
GLU B 475
LEU A 663
 NAG  B3320 (-4.3A)
None
None
None
None
 1.13A 1cmcA-4cakA:
undetectable
1cmcB-4cakA:
undetectable		 1cmcA-4cakA:
8.72
1cmcB-4cakA:
8.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1CMC_B_SAMB105_0
(MET REPRESSOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 10 GLU B 500
LEU B 502
GLU B 475
LEU A 663
GLY A 282
 None
None
None
None
NAG  B3320 (-4.3A)
 1.10A 1cmcA-4cakB:
undetectable
1cmcB-4cakB:
undetectable		 1cmcA-4cakB:
9.88
1cmcB-4cakB:
9.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1DVT_A_FLPA125_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 8 ALA B  30
LEU B 383
LEU A 562
SER B 369
 None
None
None
NAG  B3371 (-4.0A)
 0.98A 1dvtA-4cakB:
undetectable
1dvtB-4cakB:
undetectable		 1dvtA-4cakB:
10.77
1dvtB-4cakB:
10.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1EII_A_RTLA135_0
(CELLULAR
RETINOL-BINDING
PROTEIN II)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 THR A 532
ALA A 506
LYS A 726
LEU A 393
LEU A 586
 None
 1.38A 1eiiA-4cakA:
undetectable		 1eiiA-4cakA:
8.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1HK1_A_T44A3004_1
(SERUM ALBUMIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 PHE B 370
PHE B 455
LEU B 425
VAL B 427
 None
 1.01A 1hk1A-4cakB:
undetectable		 1hk1A-4cakB:
20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1HK2_A_T44A3002_1
(SERUM ALBUMIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 GLN A 593
ASN A 727
LEU A 460
LEU A 612
 None
 1.20A 1hk2A-4cakA:
undetectable		 1hk2A-4cakA:
21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1HK3_A_T44A3004_1
(SERUM ALBUMIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 PHE B 370
PHE B 455
LEU B 425
VAL B 427
 None
 0.94A 1hk3A-4cakB:
undetectable		 1hk3A-4cakB:
20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1I9J_H_TESH1010_1
(RECOMBINANT
MONOCLONAL
ANTI-TESTOSTERONE
FAB FRAGMENT HEAVY
CHAIN
RECOMBINANT
MONOCLONAL
ANTI-TESTOSTERONE
FAB FRAGMENT LIGHT
CHAIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 11 SER B 510
GLU A 283
TYR A 313
GLY A 282
LEU A 264
 NAG  B3320 (-1.5A)
None
None
NAG  B3320 (-4.3A)
NAG  B3320 ( 3.1A)
 1.43A 1i9jH-4cakB:
2.7
1i9jL-4cakB:
2.3		 1i9jH-4cakB:
15.34
1i9jL-4cakB:
15.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IE4_B_T44B328_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 GLU A  49
ALA A  89
LEU A  72
ALA A 108
 None
 0.91A 1ie4B-4cakA:
0.8
1ie4D-4cakA:
0.7		 1ie4B-4cakA:
10.80
1ie4D-4cakA:
10.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IE9_A_VDXA500_1
(VITAMIN D3 RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 SER B 121
SER B 337
VAL B 314
LEU A 322
HIS B 255
 None
 1.17A 1ie9A-4cakB:
undetectable		 1ie9A-4cakB:
16.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IOL_A_ESTA400_1
(ESTROGENIC 17-BETA
HYDROXYSTEROID
DEHYDROGENASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 11 GLY A 184
LEU A 195
GLY A 187
TYR A 274
GLU A 268
 None
 1.38A 1iolA-4cakA:
undetectable		 1iolA-4cakA:
16.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JHO_A_NIOA991_1
(NICOTINATE
MONONUCLEOTIDE:5,6-D
IMETHYLBENZIMIDAZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.23A 1jhoA-4cakB:
undetectable		 1jhoA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JHR_A_NIOA991_1
(NICOTINATE
MONONUCLEOTIDE:5,6-D
IMETHYLBENZIMIDAZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.22A 1jhrA-4cakB:
1.4		 1jhrA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JHY_A_NIOA991_1
(NICOTINATE
MONONUCLEOTIDE:5,6-D
IMETHYLBENZIMIDAZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.23A 1jhyA-4cakB:
undetectable		 1jhyA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JU6_A_LYAA317_1
(THYMIDYLATE SYNTHASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 11 PHE B 153
ILE B 131
LEU B 138
GLY B 135
PHE B 203
 None
 1.36A 1ju6A-4cakB:
undetectable		 1ju6A-4cakB:
17.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1KGL_A_RTLA175_0
(CELLULAR
RETINOL-BINDING
PROTEIN TYPE I)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 PHE B 223
ALA B 257
PRO B 163
TYR A 313
GLY A 349
 None
 1.27A 1kglA-4cakB:
undetectable		 1kglA-4cakB:
10.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1L4N_A_NIOA991_1
(NICOTINATE-NUCLEOTID
E--DIMETHYLBENZIMIDA
ZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.22A 1l4nA-4cakB:
undetectable		 1l4nA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1L5K_A_NIOA991_1
(NICOTINATE-NUCLEOTID
E--DIMETHYLBENZIMIDA
ZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.24A 1l5kA-4cakB:
undetectable		 1l5kA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1L5L_A_NIOA991_1
(NICOTINATE-NUCLEOTID
E--DIMETHYLBENZIMIDA
ZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.24A 1l5lA-4cakB:
undetectable		 1l5lA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1L5M_A_NIOA991_1
(NICOTINATE-NUCLEOTID
E--DIMETHYLBENZIMIDA
ZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.24A 1l5mA-4cakB:
undetectable		 1l5mA-4cakB:
18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 ASP A 589
ASP A 367
SER A 396
ALA A 650
ASP A 373
 None
 1.46A 1m4dA-4cakA:
undetectable		 1m4dA-4cakA:
11.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 9 ASP A 589
ASP A 367
SER A 396
ALA A 650
ASP A 373
 None
 1.50A 1m4dB-4cakA:
0.0		 1m4dB-4cakA:
11.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MXD_A_ACRA732_1
(ALPHA AMYLASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 463
GLU A 642
GLY A 643
GLY A 603
ASP A 511
 None
NAG  B3452 (-3.9A)
NAG  B3452 (-2.8A)
None
None
 1.02A 1mxdA-4cakB:
undetectable		 1mxdA-4cakB:
19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1MXG_A_ACRA442_1
(ALPHA AMYLASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 11 GLY B 463
GLU A 642
GLY A 643
GLY A 603
ASP A 511
 None
NAG  B3452 (-3.9A)
NAG  B3452 (-2.8A)
None
None
 0.98A 1mxgA-4cakB:
undetectable		 1mxgA-4cakB:
19.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1N2X_A_SAMA401_0
(S-ADENOSYL-METHYLTRA
NSFERASE MRAW)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 GLY A 398
GLU A 688
GLY A 690
ASP A 305
VAL A 298
 None
 1.24A 1n2xA-4cakA:
undetectable		 1n2xA-4cakA:
14.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1N2X_A_SAMA401_0
(S-ADENOSYL-METHYLTRA
NSFERASE MRAW)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 GLY A 398
GLU A 688
GLY A 690
VAL A 685
VAL A 298
 None
 0.91A 1n2xA-4cakA:
undetectable		 1n2xA-4cakA:
14.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1NV8_A_SAMA300_0
(HEMK PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 GLY A 265
GLY A 282
VAL A 267
PRO B 163
ALA A 310
 None
NAG  B3320 (-4.3A)
None
None
None
 1.07A 1nv8A-4cakA:
undetectable		 1nv8A-4cakA:
15.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1NV8_B_SAMB301_0
(HEMK PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 GLY A 265
GLY A 282
VAL A 267
PRO B 163
ALA A 310
 None
NAG  B3320 (-4.3A)
None
None
None
 1.02A 1nv8B-4cakA:
undetectable		 1nv8B-4cakA:
15.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ONI_B_BEZB503_0
(14.5 KDA
TRANSLATIONAL
INHIBITOR PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ALA A 583
TYR A 432
ILE A 498
PRO A 499
 None
 1.15A 1oniB-4cakA:
undetectable
1oniC-4cakA:
undetectable		 1oniB-4cakA:
9.67
1oniC-4cakA:
9.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ONI_E_BEZE509_0
(14.5 KDA
TRANSLATIONAL
INHIBITOR PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 TYR A 432
ILE A 498
PRO A 499
ALA A 583
 None
 1.08A 1oniD-4cakA:
undetectable
1oniE-4cakA:
undetectable		 1oniD-4cakA:
9.67
1oniE-4cakA:
9.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ONI_H_BEZH515_0
(14.5 KDA
TRANSLATIONAL
INHIBITOR PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ALA A 583
TYR A 432
ILE A 498
PRO A 499
 None
 1.16A 1oniH-4cakA:
undetectable
1oniI-4cakA:
undetectable		 1oniH-4cakA:
9.67
1oniI-4cakA:
9.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1PK2_A_ACAA91_1
(TISSUE-TYPE
PLASMINOGEN
ACTIVATOR)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 VAL A 454
ASP A 426
ASP A 428
LEU A 504
 None
 1.23A 1pk2A-4cakA:
undetectable		 1pk2A-4cakA:
7.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1QAB_E_RTLE1_0
(PROTEIN (RETINOL
BINDING PROTEIN))		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 11 PHE B 248
LEU A 322
ALA B 252
MET B 124
LEU B 343
 None
 1.06A 1qabE-4cakB:
undetectable		 1qabE-4cakB:
13.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1QCA_A_FUAA221_1
(TYPE III
CHLORAMPHENICOL
ACETYLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 PHE A 204
SER A 144
PHE A 131
LEU A  68
 None
 1.11A 1qcaA-4cakA:
undetectable		 1qcaA-4cakA:
12.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1QHS_A_CLMA999_0
(PROTEIN
(CHLORAMPHENICOL
PHOSPHOTRANSFERASE))		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 VAL B 359
ILE B 416
ILE B 399
PHE B 100
PHE B 370
 None
 1.02A 1qhsA-4cakB:
undetectable		 1qhsA-4cakB:
14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1RL8_A_RITA9001_2
(PROTEASE RETROPEPSIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		6 / 12 LEU B 258
GLY A 309
ALA A 310
GLY A 349
PRO B 290
ILE B 256
 None
 1.44A 1rl8B-4cakB:
undetectable		 1rl8B-4cakB:
8.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1TLM_A_MILA128_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 LEU A 567
LEU A 460
SER A 728
 None
 0.59A 1tlmA-4cakA:
undetectable		 1tlmA-4cakA:
8.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UAK_A_SAMA301_0
(TRNA
(GUANINE-N(1)-)-METH
YLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 SER A 220
VAL A 182
LEU A 183
GLY A 148
PRO A 145
 None
 0.88A 1uakA-4cakA:
undetectable		 1uakA-4cakA:
16.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1YNN_C_RFPC1120_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ARG B  67
GLN B  82
GLN B  79
ARG B 143
LEU B 145
 None
 1.48A 1ynnC-4cakB:
undetectable		 1ynnC-4cakB:
19.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ZQ9_A_SAMA4000_0
(PROBABLE
DIMETHYLADENOSINE
TRANSFERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ILE B 391
GLY B 504
VAL B 247
ILE B 114
SER B  74
 None
 1.21A 1zq9A-4cakB:
undetectable		 1zq9A-4cakB:
15.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2BM9_A_SAMA301_0
(CEPHALOSPORIN
HYDROXYLASE CMCI)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A   3
LEU A 366
GLY A 423
ALA A 361
ALA A 359
 None
 1.11A 2bm9A-4cakA:
undetectable		 2bm9A-4cakA:
12.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2BR4_B_SAMB301_0
(CEPHALOSPORIN
HYDROXYLASE CMCI)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 LEU A 567
GLY A 643
ASN B 444
ARG A 597
ALA A 644
 None
NAG  B3452 (-2.8A)
None
None
None
 1.03A 2br4B-4cakA:
undetectable		 2br4B-4cakA:
12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2BR4_D_SAMD301_1
(CEPHALOSPORIN
HYDROXYLASE CMCI)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 LYS B 384
ASP A 554
ASP A 560
 None
 1.01A 2br4D-4cakB:
undetectable		 2br4D-4cakB:
16.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2CBR_A_A80A201_1
(PROTEIN (CRABP-I))		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 786
VAL A 748
THR A 793
VAL A 794
GLY A 822
 None
 1.17A 2cbrA-4cakA:
undetectable		 2cbrA-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HC4_A_VDXA525_1
(VITAMIN D RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 393
SER A 404
VAL A 298
LEU A 307
LEU A 672
 None
NAG  A3570 (-4.7A)
None
None
None
 1.31A 2hc4A-4cakA:
undetectable		 2hc4A-4cakA:
15.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 ASP B 288
PRO B 290
VAL B 231
LEU A 390
 None
 1.05A 2hdnE-4cakB:
undetectable
2hdnF-4cakB:
undetectable
2hdnH-4cakB:
undetectable		 2hdnE-4cakB:
4.54
2hdnF-4cakB:
17.29
2hdnH-4cakB:
17.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HND_A_NVPA999_1
(REVERSE
TRANSCRIPTASE/RIBONU
CLEASE H)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 VAL A 239
GLY A 236
TRP A 113
LEU A 221
TYR A 274
 None
 1.40A 2hndA-4cakA:
undetectable		 2hndA-4cakA:
19.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HNY_A_NVPA999_1
(REVERSE
TRANSCRIPTASE/RIBONU
CLEASE H)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 VAL A 239
GLY A 236
TRP A 113
LEU A 221
TYR A 274
 None
 1.39A 2hnyA-4cakA:
undetectable		 2hnyA-4cakA:
19.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2J9D_A_ACTA1117_0
(HYPOTHETICAL
NITROGEN REGULATORY
PII-LIKE PROTEIN
MJ0059)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 ASP A 560
ARG A 559
ARG B 447
 None
 0.98A 2j9dA-4cakA:
undetectable
2j9dC-4cakA:
undetectable		 2j9dA-4cakA:
8.57
2j9dC-4cakA:
8.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2NV4_A_SAMA201_0
(UPF0066 PROTEIN
AF_0241)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 GLN A 513
GLY B 382
LEU A 600
ASP A 560
SER B 385
 None
None
NAG  B3371 (-3.2A)
None
NAG  B3452 ( 4.9A)
 1.33A 2nv4A-4cakA:
undetectable		 2nv4A-4cakA:
10.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2NYU_A_SAMA201_1
(PUTATIVE RIBOSOMAL
RNA
METHYLTRANSFERASE 2)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 4 PRO A 515
ASP A 511
ASP A 605
ASP A 560
 None
 1.02A 2nyuA-4cakA:
undetectable		 2nyuA-4cakA:
13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2OTF_A_2TNA201_1
(PHOSPHOLIPASE A2
VRV-PL-VIIIA)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 LEU A 306
ILE A 360
SER A 292
GLY A 290
 None
 0.72A 2otfA-4cakA:
undetectable		 2otfA-4cakA:
7.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PNC_A_CLUA808_1
(COPPER AMINE
OXIDASE, LIVER
ISOZYME)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 ALA B 172
TYR B 178
ASP A 232
TYR A 234
 None
 1.20A 2pncA-4cakB:
undetectable		 2pncA-4cakB:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PNC_B_CLUB809_1
(COPPER AMINE
OXIDASE, LIVER
ISOZYME)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 ALA B 172
TYR B 178
ASP A 232
TYR A 234
 None
 1.22A 2pncB-4cakB:
1.0		 2pncB-4cakB:
20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2R2V_D_ACTD36_0
(GCN4 LEUCINE ZIPPER)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 SER B 282
TYR B 281
HIS B 280
 None
 0.73A 2r2vD-4cakB:
undetectable		 2r2vD-4cakB:
4.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VDM_B_AGGB1462_1
(INTEGRIN ALPHA-IIB
INTEGRIN BETA-3)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 PHE B 153
TYR B 116
LEU B 246
SER B 123
SER B 121
 None
 1.22A 2vdmA-4cakB:
undetectable
2vdmB-4cakB:
19.4		 2vdmA-4cakB:
21.78
2vdmB-4cakB:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VDM_B_AGGB1462_1
(INTEGRIN ALPHA-IIB
INTEGRIN BETA-3)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		6 / 12 SER B 121
TYR B 122
ARG B 214
ASN B 215
ALA B 218
GLU B 220
 None
 0.59A 2vdmA-4cakB:
undetectable
2vdmB-4cakB:
19.4		 2vdmA-4cakB:
21.78
2vdmB-4cakB:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VDM_B_AGGB1462_1
(INTEGRIN ALPHA-IIB
INTEGRIN BETA-3)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 SER B 121
TYR B 122
SER B 123
ARG B 214
ASN B 215
 None
 0.50A 2vdmA-4cakB:
undetectable
2vdmB-4cakB:
19.4		 2vdmA-4cakB:
21.78
2vdmB-4cakB:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VMY_A_FFOA505_1
(SERINE
HYDROXYMETHYLTRANSFE
RASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 VAL A 255
SER A  96
ALA A  95
PRO A 186
GLY A 187
 None
 1.18A 2vmyB-4cakA:
undetectable		 2vmyB-4cakA:
17.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2WEK_B_DIFB1374_1
(ZINC-BINDING ALCOHOL
DEHYDROGENASE
DOMAIN-CONTAINING
PROTEIN 2)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 TYR B 281
ILE B 304
ASN B 269
LEU B 294
 None
 1.27A 2wekB-4cakB:
undetectable		 2wekB-4cakB:
19.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2X7H_A_PFNA1374_1
(ZINC-BINDING ALCOHOL
DEHYDROGENASE
DOMAIN-CONTAINING
PROTEIN 2)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 PRO A 564
SER A 563
LYS B 384
GLU B 356
 NAG  B3452 (-3.8A)
None
None
None
 1.46A 2x7hA-4cakA:
undetectable		 2x7hA-4cakA:
17.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XCT_G_CPFG1020_1
(DNA GYRASE SUBUNIT
B, DNA GYRASE
SUBUNIT A)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 ARG B 578
GLY B 579
SER B 677
 None
 0.56A 2xctB-4cakB:
undetectable		 2xctB-4cakB:
21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7W_C_SALC1300_1
(LYSR-TYPE REGULATORY
PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 THR A 350
GLY B 293
PHE A 356
PHE A 392
 None
 0.81A 2y7wC-4cakA:
undetectable		 2y7wC-4cakA:
13.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7W_C_SALC1300_1
(LYSR-TYPE REGULATORY
PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 THR B 296
GLY B 293
PHE A 356
PHE A 392
 None
 0.84A 2y7wC-4cakB:
undetectable		 2y7wC-4cakB:
14.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_A_ZMRA1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
GLU A 594
 None
 1.05A 2ya7A-4cakA:
7.2		 2ya7A-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_A_ZMRA1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
TYR A 645
 None
 0.98A 2ya7A-4cakA:
7.2		 2ya7A-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_B_ZMRB1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
GLU A 594
 None
 1.01A 2ya7B-4cakA:
5.8		 2ya7B-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_B_ZMRB1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
TYR A 645
 None
 0.95A 2ya7B-4cakA:
5.8		 2ya7B-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_D_ZMRD1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
GLU A 594
 None
 1.04A 2ya7D-4cakA:
7.5		 2ya7D-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YA7_D_ZMRD1776_2
(NEURAMINIDASE A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 ASP A 605
ILE A 487
LEU A 508
TYR A 645
 None
 0.96A 2ya7D-4cakA:
7.5		 2ya7D-4cakA:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2YJA_B_ESTB1550_1
(ESTROGEN RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ALA B 229
LEU B 246
ILE B 325
GLY A 349
LEU B 294
 None
 1.19A 2yjaB-4cakB:
undetectable		 2yjaB-4cakB:
15.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Z54_A_AB1A200_2
(HIV-1 PROTEASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		6 / 12 ARG A 317
ALA B 225
ASP B 224
GLY B 271
VAL A 325
ILE B 226
 None
 1.18A 2z54B-4cakA:
undetectable		 2z54B-4cakA:
7.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ZLC_A_VDXA500_1
(VITAMIN D3 RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 393
SER A 404
VAL A 298
LEU A 307
LEU A 672
 None
NAG  A3570 (-4.7A)
None
None
None
 1.31A 2zlcA-4cakA:
undetectable		 2zlcA-4cakA:
14.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3A3Y_A_OBNA6000_1
(NA, K-ATPASE ALPHA
SUBUNIT)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 10 PHE B 223
GLY A 354
VAL B 231
PHE B 248
LEU B 117
 None
 1.40A 3a3yA-4cakB:
undetectable		 3a3yA-4cakB:
20.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3A8I_A_C2FA401_0
(AMINOMETHYLTRANSFERA
SE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 TYR B 289
ASP B 259
ILE B 226
VAL A 325
TYR B 318
 None
 1.33A 3a8iA-4cakB:
undetectable		 3a8iA-4cakB:
18.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3A8I_D_C2FD401_0
(AMINOMETHYLTRANSFERA
SE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 TYR B 289
ASP B 259
ILE B 226
VAL A 325
TYR B 318
 None
 1.33A 3a8iD-4cakB:
undetectable		 3a8iD-4cakB:
18.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3AQI_B_CHDB5_0
(FERROCHELATASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 PRO A 468
LEU A 552
ARG A 553
 None
 0.79A 3aqiB-4cakA:
undetectable		 3aqiB-4cakA:
16.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3C6G_A_VD3A701_1
(CYTOCHROME P450 2R1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 LEU B 138
ALA B 347
THR B 146
VAL B 112
ILE B 114
 None
 1.08A 3c6gA-4cakB:
undetectable		 3c6gA-4cakB:
21.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CZH_B_D2VB602_1
(CYTOCHROME P450 2R1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 LEU B 138
ALA B 347
THR B 146
VAL B 112
ILE B 114
 None
 1.13A 3czhB-4cakB:
undetectable		 3czhB-4cakB:
21.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DH0_B_SAMB300_0
(SAM DEPENDENT
METHYLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 PHE A  21
GLY A  52
GLY A  94
VAL A  37
THR A  42
 None
 1.14A 3dh0B-4cakA:
undetectable		 3dh0B-4cakA:
12.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3DOU_A_SAMA1_0
(RIBOSOMAL RNA LARGE
SUBUNIT
METHYLTRANSFERASE J)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 ALA A 647
PRO A 610
GLY A 643
GLN A 611
ALA A 638
 None
NAG  B3453 (-4.6A)
NAG  B3452 (-2.8A)
NAG  B3453 (-3.8A)
NAG  B3453 (-2.5A)
 0.89A 3douA-4cakA:
undetectable		 3douA-4cakA:
10.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3EKX_B_1UNB201_2
(PROTEASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		6 / 11 ARG A 317
ALA B 225
ASP B 224
GLY B 271
VAL A 325
ILE B 226
 None
 1.27A 3ekxB-4cakA:
undetectable		 3ekxB-4cakA:
7.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3EKX_B_1UNB201_2
(PROTEASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		6 / 11 ARG A 317
ALA B 225
ASP B 224
ILE B 236
VAL A 325
ILE B 226
 None
 1.46A 3ekxB-4cakA:
undetectable		 3ekxB-4cakA:
7.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ELZ_A_CHDA152_0
(ILEAL BILE
ACID-BINDING PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 VAL B 664
LYS B 658
HIS A 927
 None
 0.88A 3elzA-4cakB:
undetectable		 3elzA-4cakB:
11.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3FI0_D_TRPD1001_0
(TRYPTOPHANYL-TRNA
SYNTHETASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 9 GLY A  62
GLN A  64
ILE A  35
VAL A 447
GLN A 444
 None
 1.41A 3fi0D-4cakA:
undetectable		 3fi0D-4cakA:
15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3FI0_R_TRPR1001_0
(TRYPTOPHANYL-TRNA
SYNTHETASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 9 GLY A  62
GLN A  64
ILE A  35
VAL A 447
GLN A 444
 None
 1.46A 3fi0R-4cakA:
undetectable		 3fi0R-4cakA:
15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HCR_A_CHDA424_0
(FERROCHELATASE,
MITOCHONDRIAL)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 PRO A 945
SER A 943
GLY A 790
PRO A 791
 None
 1.16A 3hcrA-4cakA:
undetectable		 3hcrA-4cakA:
16.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3I9J_B_NCAB302_0
(ADP-RIBOSYL CYCLASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 6 GLU B 297
ASN B 303
SER B 291
PHE A 356
 None
 1.22A 3i9jB-4cakB:
undetectable		 3i9jB-4cakB:
18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K4V_B_ROCB201_4
(HIV-1 PROTEASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 4 ARG A 422
ASP A 367
GLY A 394
THR A 296
 None
 1.47A 3k4vB-4cakA:
undetectable		 3k4vB-4cakA:
5.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 THR A 150
ALA A 122
GLY A 184
ALA A 169
SER A 222
 None
 1.04A 3mg02-4cakA:
undetectable
3mg0V-4cakA:
undetectable		 3mg02-4cakA:
10.89
3mg0V-4cakA:
14.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 11 THR A 150
ALA A 122
GLY A 184
ALA A 169
SER A 222
 None
 1.03A 3mg0N-4cakA:
undetectable		 3mg0N-4cakA:
10.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OWX_A_XRAA233_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY A 349
GLY B 293
VAL A 406
GLU A 315
ILE B 304
 None
 1.13A 3owxA-4cakA:
undetectable		 3owxA-4cakA:
13.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3P2K_A_SAMA6735_1
(16S RRNA METHYLASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 ASP A 560
GLU B  55
SER B 385
 None
None
NAG  B3452 ( 4.9A)
 0.85A 3p2kA-4cakA:
undetectable		 3p2kA-4cakA:
12.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5S_A_ACHA1289_0
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 6 VAL B 507
ASN B 320
TYR A 313
GLU B 475
 None
NAG  B3320 (-1.8A)
None
None
 1.14A 3q5sA-4cakB:
undetectable		 3q5sA-4cakB:
16.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3R75_A_BEZA701_0
(ANTHRANILATE/PARA-AM
INOBENZOATE
SYNTHASES COMPONENT
I)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 GLU B 475
GLY B 327
THR A 348
GLU A 315
THR B 329
 None
 1.39A 3r75A-4cakB:
undetectable		 3r75A-4cakB:
21.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3R75_B_BEZB701_0
(ANTHRANILATE/PARA-AM
INOBENZOATE
SYNTHASES COMPONENT
I)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 GLU B 475
GLY B 327
THR A 348
GLU A 315
THR B 329
 None
 1.37A 3r75B-4cakB:
undetectable		 3r75B-4cakB:
21.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3R76_A_BEZA701_0
(ANTHRANILATE/PARA-AM
INOBENZOATE
SYNTHASES COMPONENT
I)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 11 GLU B 475
GLY B 327
THR A 348
GLU A 315
THR B 329
 None
 1.39A 3r76A-4cakB:
undetectable		 3r76A-4cakB:
21.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3R76_B_BEZB701_0
(ANTHRANILATE/PARA-AM
INOBENZOATE
SYNTHASES COMPONENT
I)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 11 GLU B 475
GLY B 327
THR A 348
GLU A 315
THR B 329
 None
 1.38A 3r76B-4cakB:
undetectable		 3r76B-4cakB:
21.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TF1_A_ACTA191_0
(METHYL-ACCEPTING
CHEMOTAXIS PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 THR A 596
ILE A 565
PHE A 485
LEU A 567
 None
 1.45A 3tf1A-4cakA:
undetectable		 3tf1A-4cakA:
10.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3VHU_A_SNLA1001_2
(MINERALOCORTICOID
RECEPTOR)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 LEU B 299
LEU B 292
SER B 291
MET B 227
 None
 1.01A 3vhuA-4cakB:
undetectable		 3vhuA-4cakB:
19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_A_W9TA1004_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.03A 3w9tA-4cakB:
undetectable		 3w9tA-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_B_W9TB502_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.01A 3w9tB-4cakB:
undetectable		 3w9tB-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_C_W9TC1002_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.02A 3w9tC-4cakB:
undetectable		 3w9tC-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_D_W9TD507_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 ASP A 305
GLU A 688
GLY A 398
ASP A 301
 None
 1.19A 3w9tD-4cakA:
undetectable		 3w9tD-4cakA:
17.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_D_W9TD512_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.03A 3w9tD-4cakB:
undetectable		 3w9tD-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_E_W9TE502_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.02A 3w9tE-4cakB:
undetectable		 3w9tE-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_F_W9TF503_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.02A 3w9tF-4cakB:
undetectable		 3w9tF-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3W9T_G_W9TG502_1
(HEMOLYTIC LECTIN
CEL-III)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 GLU B 220
GLY B 221
TYR B 318
GLU A 324
 None
 1.01A 3w9tG-4cakB:
undetectable		 3w9tG-4cakB:
21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WDM_A_ADNA901_1
(4-PHOSPHOPANTOATE--B
ETA-ALANINE LIGASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 9 ALA A 439
GLY A 418
LEU A  23
LEU A 421
ILE A 436
 None
 1.37A 3wdmA-4cakA:
undetectable		 3wdmA-4cakA:
13.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A97_A_ZPCA1318_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 GLU A 324
PHE B 248
HIS B 274
VAL B 193
 None
 1.07A 4a97A-4cakA:
2.3		 4a97A-4cakA:
16.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A9K_A_TYLA2200_1
(CREB-BINDING PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 VAL A 888
LEU A 803
ILE A 815
VAL A 903
 None
 0.74A 4a9kA-4cakA:
undetectable		 4a9kA-4cakA:
8.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4A9K_A_TYLA2200_1
(CREB-BINDING PROTEIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 VAL B 340
LEU B 134
ILE B 131
VAL B 247
 None
 0.85A 4a9kA-4cakB:
undetectable		 4a9kA-4cakB:
11.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AC9_C_DXCC1476_0
(MJ0495-LIKE PROTEIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 ILE A 699
ALA A 697
MET A 693
ARG A 402
 None
NAG  B3452 (-3.3A)
None
None
 1.26A 4ac9B-4cakA:
undetectable
4ac9C-4cakA:
undetectable		 4ac9B-4cakA:
18.76
4ac9C-4cakA:
18.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ACA_C_DXCC1476_0
(TRANSLATION
ELONGATION FACTOR
SELB)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 ILE A 699
ALA A 697
MET A 693
ARG A 402
 None
NAG  B3452 (-3.3A)
None
None
 1.26A 4acaB-4cakA:
undetectable
4acaC-4cakA:
undetectable		 4acaB-4cakA:
18.76
4acaC-4cakA:
18.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGA_A_ACTA1131_0
(LYSOZYME C)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 ASN B   3
ASP B  39
ASN B  43
 None
 0.78A 4agaA-4cakB:
undetectable		 4agaA-4cakB:
10.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4BLV_A_SAMA1281_0
(RIBOSOMAL RNA LARGE
SUBUNIT
METHYLTRANSFERASE J)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 586
GLY A 370
GLY A 300
ASP A 369
GLY A 495
 None
 0.97A 4blvA-4cakA:
undetectable		 4blvA-4cakA:
15.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DQC_A_017A101_1
(ASPARTYL PROTEASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 10 ARG A 317
ALA B 225
ASP B 224
GLY B 271
VAL A 325
 None
 1.09A 4dqcA-4cakA:
undetectable		 4dqcA-4cakA:
7.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4FGL_C_CLQC303_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 8 GLY B 221
PHE B 248
ILE B 226
PHE B 308
 None
 0.82A 4fglD-4cakB:
undetectable		 4fglD-4cakB:
15.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4FGL_D_CLQD303_0
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 GLY B 221
PHE B 248
ILE B 226
PHE B 308
 None
 0.76A 4fglC-4cakB:
2.3		 4fglC-4cakB:
15.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4FU9_A_ACTA311_0
(UROKINASE-TYPE
PLASMINOGEN
ACTIVATOR)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 GLN A 509
THR A 531
THR A 532
 None
 0.82A 4fu9A-4cakA:
undetectable		 4fu9A-4cakA:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4FUF_A_ACTA310_0
(UROKINASE-TYPE
PLASMINOGEN
ACTIVATOR)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 GLN A 509
THR A 531
THR A 532
 None
 0.80A 4fufA-4cakA:
undetectable		 4fufA-4cakA:
13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0V_D_MIXD101_1
(DNA TOPOISOMERASE
2-BETA)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 ARG A 519
GLY A 518
GLU B 456
GLN A 528
 None
 1.21A 4g0vB-4cakA:
undetectable		 4g0vB-4cakA:
22.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G19_D_ACTD302_0
(GLUTATHIONE
TRANSFERASE GTE1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 TYR B 348
PHE B 421
ARG B 352
 None
 1.21A 4g19D-4cakB:
undetectable		 4g19D-4cakB:
16.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I1R_A_LZUA801_1
(MUCOSA-ASSOCIATED
LYMPHOID TISSUE
LYMPHOMA
TRANSLOCATION
PROTEIN 1)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 VAL A 618
PHE A 719
LEU A 737
LEU A 738
LEU A 614
 None
 1.11A 4i1rA-4cakA:
undetectable		 4i1rA-4cakA:
18.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JTP_A_ASCA802_0
(RRNA N-GLYCOSIDASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 TYR B 348
ILE B 344
ASN B 305
ILE B 114
 None
 1.09A 4jtpA-4cakB:
undetectable		 4jtpA-4cakB:
16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KHP_A_PARA1606_1
(16S RIBOSOMAL RNA
30S RIBOSOMAL
PROTEIN S9
30S RIBOSOMAL
PROTEIN S10)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 TYR A 645
ARG A 512
SER A 568
 None
 1.11A 4khpI-4cakA:
undetectable
4khpJ-4cakA:
undetectable		 4khpI-4cakA:
9.51
4khpJ-4cakA:
6.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KLR_A_CHDA504_0
(FERROCHELATASE,
MITOCHONDRIAL)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 LEU A  93
ARG A 140
PRO A  45
SER A  46
 None
 1.16A 4klrA-4cakA:
undetectable		 4klrA-4cakA:
17.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KQ8_A_ASDA602_1
(CYTOCHROME P450 19A1)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 10 ARG A 327
ILE B 325
ILE B 226
ALA A 323
VAL B 507
 None
 1.30A 4kq8A-4cakA:
undetectable		 4kq8A-4cakA:
18.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KQI_A_NIOA403_1
(NICOTINATE-NUCLEOTID
E--DIMETHYLBENZIMIDA
ZOLE
PHOSPHORIBOSYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 9 GLY B 595
GLY B 577
SER B 576
GLU B 599
GLY B 579
 None
 1.20A 4kqiA-4cakB:
undetectable		 4kqiA-4cakB:
17.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4KTV_A_ADNA403_1
(S-ADENOSYLMETHIONINE
SYNTHASE ISOFORM
TYPE-2)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 LYS B 519
SER B 322
ASP B 484
ILE B 351
ILE B 307
 None
 1.46A 4ktvA-4cakB:
undetectable
4ktvB-4cakB:
undetectable		 4ktvA-4cakB:
20.14
4ktvB-4cakB:
20.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF7_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 TYR A 645
ARG A 512
SER A 568
 None
 1.17A 4lf7I-4cakA:
undetectable
4lf7J-4cakA:
undetectable		 4lf7I-4cakA:
9.41
4lf7J-4cakA:
7.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LF8_A_PARA1817_1
(16S RRNA
RIBOSOMAL PROTEIN S9
RIBOSOMAL PROTEIN
S10)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 TYR A 645
ARG A 512
SER A 568
 None
 1.17A 4lf8I-4cakA:
undetectable
4lf8J-4cakA:
undetectable		 4lf8I-4cakA:
9.41
4lf8J-4cakA:
7.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4N09_C_ADNC401_2
(ADENOSINE KINASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 ASN A 629
LEU A 631
SER A 706
LEU A 653
 None
 0.94A 4n09C-4cakA:
undetectable		 4n09C-4cakA:
17.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4N49_A_SAMA601_1
(CAP-SPECIFIC MRNA
(NUCLEOSIDE-2'-O-)-M
ETHYLTRANSFERASE 1)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 4 ASN B 371
GLY B 382
ASP A 554
ASP A 560
 NAG  B3371 (-1.9A)
None
None
None
 1.37A 4n49A-4cakB:
undetectable		 4n49A-4cakB:
20.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OBW_D_SAMD601_0
(2-METHOXY-6-POLYPREN
YL-1,4-BENZOQUINOL
METHYLASE,
MITOCHONDRIAL)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 ALA B 252
ILE B 516
ASN B 316
MET A 285
GLY B 518
 None
None
NAG  B3320 (-4.6A)
NAG  B3320 (-3.6A)
None
 1.21A 4obwD-4cakB:
undetectable		 4obwD-4cakB:
14.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OLT_A_GCSA306_1
(CHITOSANASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 SER B  74
ASP B 109
GLN B 342
 None
 0.79A 4oltA-4cakB:
undetectable
4oltB-4cakB:
undetectable		 4oltA-4cakB:
16.62
4oltB-4cakB:
16.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4P6X_A_HCYA900_1
(GLUCOCORTICOID
RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 293
LEU B 246
ARG A 317
GLN B 228
THR A 413
 None
 1.35A 4p6xA-4cakB:
undetectable		 4p6xA-4cakB:
16.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4P6X_E_HCYE900_1
(GLUCOCORTICOID
RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 293
LEU B 246
ARG A 317
GLN B 228
THR A 413
 None
 1.34A 4p6xE-4cakB:
undetectable		 4p6xE-4cakB:
16.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4P6X_G_HCYG900_1
(GLUCOCORTICOID
RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 293
LEU B 246
ARG A 317
GLN B 228
THR A 413
 None
 1.34A 4p6xG-4cakB:
undetectable		 4p6xG-4cakB:
16.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4P6X_I_HCYI900_1
(GLUCOCORTICOID
RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 293
LEU B 246
ARG A 317
GLN B 228
THR A 413
 None
 1.32A 4p6xI-4cakB:
undetectable		 4p6xI-4cakB:
16.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4PWJ_A_30ZA201_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 THR A 548
ALA A 550
LEU A 552
SER A 483
 None
 0.84A 4pwjA-4cakA:
undetectable		 4pwjA-4cakA:
9.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4PWJ_B_30ZB201_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 THR A 548
ALA A 550
LEU A 552
SER A 483
 None
 0.81A 4pwjB-4cakA:
undetectable		 4pwjB-4cakA:
9.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4PXM_B_ESTB2000_1
(ESTROGEN RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 11 ALA B 229
LEU B 246
ILE B 325
GLY A 349
LEU B 294
 None
 1.21A 4pxmB-4cakB:
undetectable		 4pxmB-4cakB:
17.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QB9_E_PARE500_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 SER B 291
LEU A 352
THR B 230
ASP B 233
GLY A 382
 None
 1.24A 4qb9E-4cakB:
undetectable		 4qb9E-4cakB:
18.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QCK_A_ASDA404_1
(3-KETOSTEROID-9-ALPH
A-MONOOXYGENASE
OXYGENASE SUBUNIT)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 LEU B 343
ALA A 323
LEU B 245
ASN B 305
GLY B 349
 None
 1.14A 4qckA-4cakB:
undetectable		 4qckA-4cakB:
19.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QOG_B_ML1B302_1
(RIBOSYLDIHYDRONICOTI
NAMIDE DEHYDROGENASE
[QUINONE])		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 GLY B 221
PHE B 248
ILE B 226
PHE B 308
 None
 0.86A 4qogA-4cakB:
2.2
4qogB-4cakB:
undetectable		 4qogA-4cakB:
15.23
4qogB-4cakB:
15.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QTU_D_SAMD301_1
(PUTATIVE
METHYLTRANSFERASE
BUD23)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 5 GLN A 527
LEU A 522
ASP A 554
ASP B  47
 None
 1.24A 4qtuD-4cakA:
undetectable		 4qtuD-4cakA:
12.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QWP_B_GCSB304_1
(CHITOSANASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 GLN B 342
SER B  74
ASP B 109
 None
 0.76A 4qwpA-4cakB:
undetectable
4qwpB-4cakB:
undetectable		 4qwpA-4cakB:
16.18
4qwpB-4cakB:
16.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TWD_G_377G401_1
(CYS-LOOP
LIGAND-GATED ION
CHANNEL)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 6 TYR B 289
TYR B 321
LEU B 292
PHE B 308
 None
 1.35A 4twdF-4cakB:
undetectable
4twdG-4cakB:
undetectable		 4twdF-4cakB:
18.10
4twdG-4cakB:
18.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4UHX_A_RTZA3009_1
(ALDEHYDE OXIDASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 GLU A 555
ARG A 553
ARG A 520
PRO A 468
 None
 1.10A 4uhxA-4cakA:
undetectable		 4uhxA-4cakA:
22.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4UUU_A_SAMA1546_0
(CYSTATHIONINE
BETA-SYNTHASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 11 LEU A 569
ASP A 369
HIS A 587
VAL A 453
ASP A 373
 None
None
None
NAG  A3570 ( 2.1A)
None
 1.36A 4uuuA-4cakA:
undetectable
4uuuB-4cakA:
undetectable		 4uuuA-4cakA:
9.65
4uuuB-4cakA:
9.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Y_A_EF2A151_1
(CEREBLON ISOFORM 4)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 ASN A 227
PHE A 231
TRP A 162
TRP A 260
 None
 1.38A 4v2yA-4cakA:
undetectable		 4v2yA-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Y_B_EF2B151_1
(CEREBLON ISOFORM 4)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 ASN A 227
PHE A 231
TRP A 162
TRP A 260
 None
 1.38A 4v2yB-4cakA:
undetectable		 4v2yB-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2Z_B_Y70B151_1
(CEREBLON ISOFORM 4)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 ASN A 227
PHE A 231
TRP A 162
TRP A 260
 None
 1.39A 4v2zB-4cakA:
undetectable		 4v2zB-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V32_A_EF2A151_1
(CEREBLON ISOFORM 4)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 ASN A 227
PHE A 231
TRP A 162
TRP A 260
 None
 1.41A 4v32A-4cakA:
undetectable		 4v32A-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XDR_A_ADNA402_1
(FAD:PROTEIN FMN
TRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 PHE B 308
LEU A 352
GLY A 326
ILE B 304
THR B 328
 None
 0.90A 4xdrA-4cakB:
undetectable		 4xdrA-4cakB:
18.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XDT_A_ACTA407_0
(FAD:PROTEIN FMN
TRANSFERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 ASP B  39
GLY B 405
ASP B  95
 None
 0.56A 4xdtA-4cakB:
undetectable		 4xdtA-4cakB:
18.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XP1_A_LDPA708_1
(DOPAMINE
TRANSPORTER, ISOFORM
B)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 10 PHE B 223
ASP B 288
ALA A 310
SER B 291
GLY A 326
 None
 1.29A 4xp1A-4cakB:
undetectable		 4xp1A-4cakB:
19.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4Y8W_A_STRA604_1
(CYTOCHROME P450
21-HYDROXYLASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 VAL B 247
VAL B 340
LEU B 341
GLY B 135
LEU B 149
 None
 0.86A 4y8wA-4cakB:
undetectable		 4y8wA-4cakB:
20.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4Y8W_B_STRB603_1
(CYTOCHROME P450
21-HYDROXYLASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 VAL B 247
VAL B 340
LEU B 341
GLY B 135
LEU B 149
 None
 0.87A 4y8wB-4cakB:
undetectable		 4y8wB-4cakB:
20.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4YJI_A_TYLA502_1
(ARYL ACYLAMIDASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 THR B 254
GLY B 222
GLY B 221
ILE B 265
 None
 0.73A 4yjiA-4cakB:
undetectable		 4yjiA-4cakB:
20.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4Z69_A_DIFA1006_1
(SERUM ALBUMIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 ILE B 226
LEU B 117
TYR B 318
GLY B 221
 None
 1.01A 4z69A-4cakB:
undetectable		 4z69A-4cakB:
20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AMJ_B_EF2B151_1
(CEREBLON ISOFORM 4)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 ASN A 227
PHE A 231
TRP A 162
TRP A 260
 None
 1.42A 5amjB-4cakA:
undetectable		 5amjB-4cakA:
8.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AYF_A_C7HA402_1
(HISTONE-LYSINE
N-METHYLTRANSFERASE
SETD7)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 TYR B 318
GLY B 221
TYR A 353
GLY A 354
 None
 0.69A 5ayfA-4cakB:
undetectable		 5ayfA-4cakB:
17.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BOJ_B_4TXB201_1
(TRANSTHYRETIN)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 THR A 548
ALA A 550
LEU A 552
SER A 483
 None
 0.81A 5bojB-4cakA:
undetectable		 5bojB-4cakA:
8.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BTA_G_MFXG101_1
(DNA GYRASE SUBUNIT A
DNA GYRASE SUBUNIT B
DNA SUBSTRATE 24-MER
TTACGTGCATAGTCATTCAT
GACC)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 SER B 337
ASP A 319
ARG A 317
GLU A 315
 None
 0.93A 5btaA-4cakB:
undetectable
5btaC-4cakB:
undetectable
5btaD-4cakB:
undetectable		 5btaA-4cakB:
20.68
5btaC-4cakB:
20.68
5btaD-4cakB:
17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5BTF_F_GFNF101_1
(DNA GYRASE SUBUNIT A
DNA GYRASE SUBUNIT B
DNA SUBSTRATE 24-MER
TTACGTGCATAGTCATTCAT
GACC)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 7 SER B 337
ASP A 319
ARG A 317
GLU A 315
 None
 0.96A 5btfA-4cakB:
undetectable
5btfB-4cakB:
undetectable
5btfC-4cakB:
undetectable		 5btfA-4cakB:
20.68
5btfB-4cakB:
17.44
5btfC-4cakB:
20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CDN_O_EVPO2101_1
(DNA GYRASE SUBUNIT A
DNA GYRASE SUBUNIT
B,DNA GYRASE SUBUNIT
B)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 SER A 733
GLY A 370
ASP A 369
GLY A 300
 None
 0.93A 5cdnC-4cakA:
undetectable
5cdnD-4cakA:
undetectable		 5cdnC-4cakA:
19.29
5cdnD-4cakA:
12.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CDN_P_EVPP2101_1
(DNA GYRASE SUBUNIT A
DNA GYRASE SUBUNIT
B,DNA GYRASE SUBUNIT
B)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 SER A 733
GLY A 370
ASP A 369
GLY A 300
 None
 0.94A 5cdnT-4cakA:
undetectable
5cdnU-4cakA:
undetectable		 5cdnT-4cakA:
19.29
5cdnU-4cakA:
12.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5DXB_B_ESTB601_1
(ESTROGEN RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 11 ALA B 229
LEU B 246
ILE B 325
GLY A 349
LEU B 294
 None
 1.21A 5dxbB-4cakB:
undetectable		 5dxbB-4cakB:
15.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5DZK_R_BEZR801_0
(ATP-DEPENDENT CLP
PROTEASE PROTEOLYTIC
SUBUNIT 2
BEZ-LEU-LEU)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 SER A 287
ALA A 286
PRO A 258
LEU A 264
 NAG  B3320 ( 4.5A)
None
None
NAG  B3320 ( 3.1A)
 0.99A 5dzkD-4cakA:
undetectable
5dzkR-4cakA:
undetectable		 5dzkD-4cakA:
12.32
5dzkR-4cakA:
2.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5DZK_R_BEZR801_1
(ATP-DEPENDENT CLP
PROTEASE PROTEOLYTIC
SUBUNIT 2
BEZ-LEU-LEU)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 SER A 754
ALA A 757
HIS A 782
LEU A 955
 None
 0.97A 5dzkd-4cakA:
undetectable
5dzkr-4cakA:
undetectable		 5dzkd-4cakA:
12.32
5dzkr-4cakA:
2.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5DZK_T_BEZT801_1
(ATP-DEPENDENT CLP
PROTEASE PROTEOLYTIC
SUBUNIT 2
BEZ-LEU-LEU)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 SER A 754
ALA A 757
HIS A 782
LEU A 955
 None
 0.94A 5dzkF-4cakA:
undetectable
5dzkT-4cakA:
undetectable		 5dzkF-4cakA:
12.32
5dzkT-4cakA:
2.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5EQB_A_1YNA602_1
(LANOSTEROL 14-ALPHA
DEMETHYLASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 GLY A  80
TYR A 155
GLY A 236
GLY A 184
HIS A 215
 None
 0.87A 5eqbA-4cakA:
undetectable		 5eqbA-4cakA:
19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5FSA_B_X2NB590_2
(CYP51 VARIANT1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 PRO B 363
LEU B  92
SER B 413
 None
 0.76A 5fsaB-4cakB:
undetectable		 5fsaB-4cakB:
20.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HW8_C_FK5C201_1
(FK506-BINDING
PROTEIN 1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 10 TYR B 318
ILE B 325
LEU B 306
PHE B 308
ILE B 167
 None
 1.30A 5hw8C-4cakB:
undetectable
5hw8H-4cakB:
undetectable		 5hw8C-4cakB:
11.03
5hw8H-4cakB:
11.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HWK_A_BEZA301_0
(GLUTATHIONE-SPECIFIC
GAMMA-GLUTAMYLCYCLOT
RANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 GLY A 418
GLY A 438
LEU A 421
LEU A 435
TYR A 448
 None
 1.28A 5hwkA-4cakA:
undetectable		 5hwkA-4cakA:
13.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HWK_B_BEZB301_0
(GLUTATHIONE-SPECIFIC
GAMMA-GLUTAMYLCYCLOT
RANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 GLY A 418
GLY A 438
LEU A 421
LEU A 435
TYR A 448
 None
 1.27A 5hwkB-4cakA:
undetectable		 5hwkB-4cakA:
13.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IEN_B_VDYB201_2
(CDL2.2)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 LEU B 262
LEU A 322
ILE B 325
TYR A 288
THR A 263
 None
 1.23A 5ienB-4cakB:
undetectable		 5ienB-4cakB:
11.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IEO_A_VDYA206_2
(CDL2.3A)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 8 ILE A 818
PRO A 820
TYR A 784
LEU A 803
 None
 0.90A 5ieoA-4cakA:
0.4		 5ieoA-4cakA:
9.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IWU_A_ERYA404_1
(MACROLIDE
2'-PHOSPHOTRANSFERAS
E II)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 6 GLY A 309
ASP B 288
ILE B 226
TYR B 321
 None
 1.13A 5iwuA-4cakA:
undetectable		 5iwuA-4cakA:
14.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5KB5_A_ADNA401_2
(ADENOSINE KINASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 4 ASN A 629
LEU A 631
SER A 706
LEU A 653
 None
 0.95A 5kb5A-4cakA:
undetectable		 5kb5A-4cakA:
18.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5KOX_A_RFPA502_2
(PENTACHLOROPHENOL
4-MONOOXYGENASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		3 / 3 VAL A 566
ARG A 724
PRO A 731
 NAG  B3452 (-3.8A)
None
None
 0.83A 5koxA-4cakA:
0.7		 5koxA-4cakA:
21.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5KVA_A_SAMA301_1
(CAFFEOYL-COA
O-METHYLTRANSFERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		3 / 3 THR B 415
SER B 424
ASP B 241
 None
 0.81A 5kvaA-4cakB:
undetectable		 5kvaA-4cakB:
17.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L6E_A_SAMA601_0
(N6-ADENOSINE-METHYLT
RANSFERASE 70 KDA
SUBUNIT)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 347
HIS A 587
GLU A 646
GLY A 394
GLY A 398
 None
 1.14A 5l6eA-4cakA:
undetectable		 5l6eA-4cakA:
13.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LG3_A_Z80A401_1
(GAMMA-AMINOBUTYRIC-A
CID RECEPTOR SUBUNIT
BETA-1)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 11 ILE A 801
VAL A 888
THR A 886
ILE A 815
ALA A 907
 None
 0.87A 5lg3A-4cakA:
2.1		 5lg3A-4cakA:
16.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LG3_E_Z80E401_1
(GAMMA-AMINOBUTYRIC-A
CID RECEPTOR SUBUNIT
BETA-1)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 ILE A 801
VAL A 888
THR A 886
ILE A 815
ALA A 907
 None
 0.87A 5lg3E-4cakA:
1.9		 5lg3E-4cakA:
16.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LG3_I_Z80I401_1
(GAMMA-AMINOBUTYRIC-A
CID RECEPTOR SUBUNIT
BETA-1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		4 / 9 VAL B 340
ASP B 126
TRP B 129
ILE B 131
 None
 1.01A 5lg3I-4cakB:
undetectable		 5lg3I-4cakB:
18.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_E_ADNE401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		6 / 10 GLY B 293
VAL A 325
ALA A 323
ILE B 351
LEU B 246
ASN B 303
 None
 1.22A 5lw1E-4cakB:
undetectable		 5lw1E-4cakB:
7.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5M0I_B_ACTB303_0
(SWI5-DEPENDENT HO
EXPRESSION PROTEIN 2)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 VAL A 391
ASN A 570
ASP A 367
LEU A 366
 None
NAG  A3570 (-2.5A)
None
None
 1.22A 5m0iB-4cakA:
undetectable		 5m0iB-4cakA:
14.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5M24_A_9CRA501_1
(RETINOIC ACID
RECEPTOR GAMMA)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 LEU A 306
SER A 344
PHE A 289
GLY A 256
ILE A 360
 None
 1.10A 5m24A-4cakA:
undetectable		 5m24A-4cakA:
13.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5N5D_B_SAMB303_1
(METHYLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 7 GLY A 394
GLU A 648
ASP A 373
ASN A 675
 None
 1.02A 5n5dB-4cakA:
undetectable		 5n5dB-4cakA:
12.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NKN_A_LOCA201_1
(NEUTROPHIL
GELATINASE-ASSOCIATE
D LIPOCALIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 260
LEU B 292
ASP B 288
PHE B 223
THR B 254
 None
 1.32A 5nknA-4cakB:
undetectable		 5nknA-4cakB:
7.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5NWV_A_ACAA18_1
(SCRFP-TAG,GP41)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLY B 468
ASN B 449
GLU B 356
LEU B 357
GLU B 358
 None
NAG  B3452 (-3.1A)
None
None
None
 1.30A 5nwvA-4cakB:
undetectable		 5nwvA-4cakB:
4.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5O96_A_SAMA501_0
(RIBOSOMAL RNA SMALL
SUBUNIT
METHYLTRANSFERASE E)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 11 LEU A 633
GLY A 341
LEU A 721
VAL A 685
ARG A 683
 None
 1.05A 5o96A-4cakA:
undetectable
5o96B-4cakA:
undetectable		 5o96A-4cakA:
14.47
5o96B-4cakA:
14.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5O96_F_SAMF501_0
(RIBOSOMAL RNA SMALL
SUBUNIT
METHYLTRANSFERASE E)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 10 GLY A 233
GLY A 193
VAL A 255
ARG A 276
ALA A 266
 None
 1.14A 5o96E-4cakA:
undetectable
5o96F-4cakA:
undetectable		 5o96E-4cakA:
14.47
5o96F-4cakA:
14.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5P9I_A_1E8A701_2
(TYROSINE-PROTEIN
KINASE BTK)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		4 / 5 LEU B 246
TYR A 353
MET B 227
ASP B 233
 None
 1.45A 5p9iA-4cakB:
undetectable		 5p9iA-4cakB:
16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5SYE_B_TA1B502_1
(TUBULIN BETA CHAIN)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLU B 500
VAL B 507
SER B 322
GLN B 106
GLY B 349
 None
 1.15A 5syeB-4cakB:
undetectable		 5syeB-4cakB:
18.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5SYF_B_TA1B502_1
(TUBULIN BETA CHAIN)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ASP A 511
LEU B  44
ARG B  37
ARG A 519
LEU B  17
 None
 1.37A 5syfB-4cakA:
undetectable		 5syfB-4cakA:
19.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TOA_A_ESTA601_1
(ESTROGEN RECEPTOR
BETA)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ALA B 347
LEU B 343
LEU B 341
ILE B 151
LEU B 134
 None
 1.05A 5toaA-4cakB:
undetectable		 5toaA-4cakB:
16.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TWJ_A_SAMA201_0
(RIBOSOMAL RNA LARGE
SUBUNIT
METHYLTRANSFERASE H)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 LEU A 352
GLY A 354
GLY A 381
LEU B 299
SER B 300
 None
 0.86A 5twjA-4cakA:
undetectable		 5twjA-4cakA:
9.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TWJ_B_SAMB201_0
(RIBOSOMAL RNA LARGE
SUBUNIT
METHYLTRANSFERASE H)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 10 LEU A 352
GLY A 354
GLY A 381
LEU B 299
SER B 300
 None
 0.86A 5twjB-4cakA:
undetectable		 5twjB-4cakA:
9.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WM2_A_ACTA605_0
(SALICYLATE-AMP
LIGASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 THR B 328
THR A 348
ARG A 327
 None
 0.81A 5wm2A-4cakB:
undetectable		 5wm2A-4cakB:
21.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5X6Y_A_SAMA902_0
(MRNA CAPPING ENZYME
P5)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 LEU A 352
GLY B 327
ALA A 323
GLU B 476
PHE A 669
 None
 1.07A 5x6yA-4cakA:
undetectable		 5x6yA-4cakA:
20.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5X6Y_C_SAMC902_0
(MRNA CAPPING ENZYME
P5)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 12 LEU A 352
GLY B 327
ALA A 323
GLU B 476
PHE A 669
 None
 1.05A 5x6yC-4cakA:
undetectable		 5x6yC-4cakA:
20.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5X7P_A_ACRA1421_1
(GLYCOSIDE HYDROLASE
FAMILY 31
ALPHA-GLUCOSIDASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 TYR A 155
TYR A 166
GLY A 187
GLY A 193
 None
 1.15A 5x7pA-4cakA:
undetectable		 5x7pA-4cakA:
21.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XPR_A_K86A1201_1
(ENDOTHELIN B
RECEPTOR,ENDOLYSIN,E
NDOTHELIN B RECEPTOR)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 GLN A 351
LEU B 246
ARG A 317
ILE B 226
ALA B 229
 None
 1.34A 5xprA-4cakA:
undetectable		 5xprA-4cakA:
21.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZHM_B_SAMB301_1
(TRNA
(GUANINE-N(1)-)-METH
YLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		5 / 12 GLY A 290
GLY A 256
VAL A 295
LEU A 307
GLY A 309
 None
 0.80A 5zhmB-4cakA:
undetectable		 5zhmB-4cakA:
15.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6AG0_C_ACRC607_0
(ALPHA-AMYLASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		4 / 6 GLY B 293
GLY A 382
PRO A 383
GLY B 271
 None
 0.75A 6ag0C-4cakB:
undetectable		 6ag0C-4cakB:
8.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DWN_A_AQ4A602_1
(CYTOCHROME P450 1A1)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 5 ILE A 701
SER A 344
ALA A 650
LEU A 614
 None
 1.03A 6dwnA-4cakA:
undetectable		 6dwnA-4cakA:
6.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DWN_C_AQ4C602_0
(CYTOCHROME P450 1A1)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 ASP B 259
GLY B 222
PHE B 156
ILE B 325
LEU B 306
 None
 1.14A 6dwnC-4cakB:
undetectable		 6dwnC-4cakB:
9.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6EMU_C_SAMC301_0
(TRNA
(GUANINE(9)-/ADENINE
(9)-N1)-METHYLTRANSF
ERASE)		 4cak INTEGRIN BETA-3
(Homo
sapiens) 		5 / 12 PRO B 290
ILE B 304
THR B 230
ILE B 256
ILE B 325
 None
 1.03A 6emuC-4cakB:
undetectable		 6emuC-4cakB:
13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6G1P_A_ACTA403_0
(ADP-RIBOSYLHYDROLASE
LIKE 2)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		3 / 3 TYR A 380
ASP B 270
GLN B 267
 None
 0.84A 6g1pA-4cakA:
undetectable		 6g1pA-4cakA:
17.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GTQ_B_ACTB207_0
(DUF1778
DOMAIN-CONTAINING
PROTEIN
N-ACETYLTRANSFERASE)		 4cak INTEGRIN ALPHA-IIB
(Homo
sapiens) 		4 / 6 LEU A 466
THR A 596
GLY A 603
ARG A 520
 None
 1.35A 6gtqB-4cakA:
undetectable
6gtqD-4cakA:
undetectable		 6gtqB-4cakA:
11.00
6gtqD-4cakA:
4.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GZ9_A_TXCA501_0
(PEPTIDE ABC
TRANSPORTER PERMEASE)		 4cak INTEGRIN ALPHA-IIB
INTEGRIN BETA-3
(Homo
sapiens;
Homo
sapiens) 		5 / 10 ASN A 727
GLN A 611
ASN A 730
PRO A 731
ASN B 452
 None
NAG  B3453 (-3.8A)
None
None
NAG  B3452 (-1.9A)
 1.50A 6gz9A-4cakA:
0.0		 6gz9A-4cakA:
6.28